# Effectiveness of Tofacitinib in Systemic Sclerosis

> **NCT06044844** · PHASE2 · UNKNOWN · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 44 (estimated)

## Conditions studied

- Efficacy of Tofacitinib in the Systemic Sclerosis

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT06044844
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044844, "Effectiveness of Tofacitinib in Systemic Sclerosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06044844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*